生物医药

肿瘤药理、抗体工程

1.Shan Chuankun,Wang Yuexuan,Li Yi,Yang Siqi,Sheng Weijin,Liu Xiujun.The triple-drug combination DBDx enhances the antitumor efficacy of PD-1 antibody associated with Treg modulation.Journal of Cancer Research and Therapeutics, 2023,19(6):1603-1609
2.Shiming He ; Chunyan Zhao ; Hongyu Tao ; Weijin Sheng ; Ruijuan Gao ; Xiujun Liu ; Yongsu Zhen ; A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer, DrugDelivery, 2022, 29(1): 1243-1256
3.Shiming He, Jian Xu, Xiujun Liu, Yongsu Zhen. Advances and challenges in the treatment of esophageal cancer.Acta Pharmaceutica Sinica B,2021,
https://doi.org/10.1016/j.apsb.2021.03.008
4.Mengran Zhang, Hao Cai, Yue Du, Yuexuan Wang, Jianhua Gong, Jian Xu, and Xiujun Liu. Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination. Molecular Pharmaceutics, 2021 Jan 20. doi: 10.1021/acs.molpharmaceut.0c01203.
5.ChuanKun Shan, YiBo Du, XiaoTian Zhai, YueXuan Wang, Yi Li, JianHua Gong. Zhi Juan Ge,.XiuJun Liu, YongSu Zhen. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor infiltrating CD8+ T cell augmentation. Cancer Chemotherapy and Pharmacology, 2021 Jan 3. DOI: 10.1007/s00280-020-04209-7. Online ahead of print.
6. Yan-Bo Zheng, Meng-Ran Zhang, Yi Li, Xiu-Jun Liu, and Yong-Su Zhen. DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Cancer Biology & Therapy 2020 Aug 2;21(8):749-757.doi: 10.1080/15384047.2020.1776580. Epub 2020 Jun 17.
7.Jian-Hua Gong, Yan-Bo Zheng, Meng-Ran Zhang, Yue-Xuan Wang, Si-Qi Yang, Rui-Hai Wang, Qing-Fang Miao, Xiu-Jun Liu & Yong-Su Zhen.“Dexamethasone enhances the antitumor efficacy of Gemcitabine by Glucocorticoid receptor signaling” Cancer Biology & Therapy，DOI: 10.1080/15384047.2019.1702399. https://doi.org/10.1080/ 15384047.2019.1702399
8.Xu J, Du Y, Liu WJ, Li L, Li Y, Wang XF, Yi HF, Shan CK, Xia GM, Liu XJ, Zhen YS. Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. Drug Deliv., 2018, 25(1), 102-111
9.Wuli Zhao, Caixia Zhang, Chongwen Bi, Cheng Ye, Danqing Song, Xiujun Liu and Rongguang Shao.Sophoridinol derivative 05D induces tumor cells apoptosis by topoisomerase1-mediated DNA breakage. Oncotargets and Therapy. 2016(9):2805-2817
10. Liu XJ, Zheng YB#, Li Y, Wu SY, Zhen YS.A Multifunctional Drug Combination Shows Highly Potent Therapeutic Efficacy against Human Cancer Xenografts in Athymic Mice.PLoS One. 2014, 22;9(12):e115790

1.刘秀均;盛唯瑾;马兴佳;李毅;甄永苏.一种治疗肿瘤的综合靶向药物复合物及其制剂和用途, 申请号:CN2024110363999，申请日:2024.7.3
2.刘秀均;蔡豪;盛唯瑾;郑艳波;李毅;甄永苏.药物组合物在制备治疗肿瘤耐药药物中的应用, 申请号:CN2023118350827，申请日:2023.12.28
3.刘秀均;夏桂民;王莹;杨思琪;李毅;甄永苏.白消安重组人血白蛋白纳米颗粒、其制备方法与用途, 申请号:CN2023118383163,申请日:2023.12.28
4.刘秀均;盛唯瑾;郑艳波;杜怡波;于卓君;李毅;王晓飞;甄永苏.防御素-血清白蛋白重组蛋白在制备治疗或预防免疫失调药物中的应用, 申请号:CN 2023115708233,申请日:2023.11.23
5.刘秀均;郑艳波;于卓君;李毅;盛唯瑾;白利平;王莹;弓建华;甄永苏.药物组合物在制备免疫调节作用药物中的应用,申请号:CN2023102535240,申请日:2023.3.16
6.刘明亮;刘秀均;汪阿鹏;李毅;吕凯;甄永苏.含有马来酰亚胺片段的地塞米松衍生物及其制备方法,专利号：ZL202211276232.0,授权日:2022.10.19
7.王阳阳;刘秀均;李良;甄永苏;李毅.一种PEG修饰的基于叶酸受体和巨胞饮的双功能抗肿瘤重组蛋白偶联物,专利号：ZL201910405541.5,授权日:2022.8.5
8.刘明亮;刘秀均;吕凯;李毅;汪阿鹏;甄永苏.一类杂合分子化合物及其在治疗肿瘤方面的应用, 专利号：ZL202110507994.6,授权日:2022.5.27
9.刘秀均;甄永苏;郑艳波;李毅;吴淑英.具有抗肿瘤作用的药物组合物及其应用, 专利号：ZL201010133844.5,授权日:2013.8.21
10.刘秀均;甄永苏;郑艳波;李毅;吴淑英.双活性成分抗肿瘤药物及其应用,专利号：ZL201010133858.7,授权日:2013.11.6

技术咨询